Boston Scientific (BSX) Stock Price, News & Analysis

Company Overview

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation. Boston Scientific’s portfolio includes devices such as stents, catheters, cardiac rhythm management and ablation technologies, endoscopic tools, devices for treating urinary and pelvic conditions, and systems used in pain management.

The company sells its products through direct sales organizations and distributors across North America, Europe, Asia-Pacific, Latin America and other international markets. Boston Scientific is led by Michael F. Mahoney, who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $41.73 to $43.29
• 50-Day Range: $41.55 to $50.39
• 52-Week Range: $39.57 to $105.65
• Volume: 22.46 million shs
• Average Volume: 18.33 million shs
• Market Capitalization: $60.77 billion
• P/E Ratio: 17.77
• Dividend Yield: N/A
• Price Target: $61.43
• Consensus Rating: Moderate Buy

Boston Scientific Stock Analysis - MarketRank™

Boston Scientific scored higher than 96% of companies evaluated by MarketBeat, and ranked 12th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Boston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 20 buy ratings, 8 hold ratings, and 2 sell ratings.

Upside Potential

Boston Scientific has a consensus price target of $61.43, representing about 46.5% upside from its current price of $41.93.

Amount of Analyst Coverage

Boston Scientific has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: -0.63%

Earnings Growth

Earnings for Boston Scientific are expected to decrease by -0.63% in the coming year, from $3.17 to $3.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Boston Scientific is 17.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Boston Scientific is 17.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.77.

Price to Earnings Growth Ratio

Boston Scientific has a PEG Ratio of 1.03. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Boston Scientific has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.82% of the float of Boston Scientific has been sold short.

Short Interest Ratio / Days to Cover

Boston Scientific has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Boston Scientific has recently decreased by 1.70%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Boston Scientific does not currently pay a dividend.

Dividend Growth

Boston Scientific does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.01

News Sentiment

Boston Scientific has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 72 news articles for Boston Scientific this week, compared to 8 articles on an average week.

Search Interest

Only 77 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

MarketBeat Follows

21 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 110% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Boston Scientific in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $9,157,810.00 in company stock, which represents 0.0151% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Boston Scientific insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,157,810.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.34% of the stock of Boston Scientific is held by insiders.

Percentage Held by Institutions

89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/28/2026
• Today: 11/01/2026
• 2026 Stifel Healthcare Conference: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:BSX
• CIK: 885725
• Web: www.bostonscientific.com
• Phone: (508) 683-4000
• Fax: 508-683-5675
• Employees: 59,000
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Boston Scientific: $61.43
• High Price Target: $118.00
• Low Price Target: $44.00
• Potential Upside/Downside: +46.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.65
• Research Coverage: 31 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.36
• Trailing P/E Ratio: 17.77
• Forward P/E Ratio: 13.23
• P/E Growth: 1.03
• Net Income: $2.90 billion
• Net Margins: 16.62%
• Pretax Margin: 17.35%
• Return on Equity: 18.73%
• Return on Assets: 10.65%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 1.24
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $20.07 billion
• Price / Sales: 3.03
• Cash Flow: $4.03 per share
• Price / Cash Flow: 10.40
• Book Value: $16.49 per share
• Price / Book: 2.54

Miscellaneous

• Outstanding Shares: 1,449,230,000
• Free Float: 1,444,303,000
• Market Cap: $60.77 billion
• Optionable: Optionable
• Beta: 0.58